Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy

Cancer Prevention Research

Volumn 8, Issue 8, 2015, Pages 712-719

  Cipolla, Bernard G ^a   Mandron, Eric ^b   Marc Lefort, Jean ^c   Coadou, Yves ^d   Della Negra, Emmanuel ^e   Corbel, Luc ^e   Le Scodan, Ronan ^f   Rahmene Azzouzi, Abdel ^g   Mottet, Nicolas ^h  

^a centre hospitalier de Mont de Marsan   (France)

^b Technopole Université   (France)

^c Polyclinique de Lisieux   (France)

^d Clinique Saint Michel et Sainte Anne   (France)

^e Centre Hospitalier Privé de Saint Brieuc Polyclinique du Littoral Site Sainte Thérèse   (France)

^f Centre hospitalier prive Saint Gregoire   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SULFORAPHANE; ANTINEOPLASTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; SULFORAFAN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE; BLOATING; BLOOD CHEMISTRY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; COMPLICATION; DRUG THERAPY; ETIOLOGY; FOLLOW UP; PATHOLOGY; PILOT STUDY; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

AGED; ANTICARCINOGENIC AGENTS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; ISOTHIOCYANATES; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84942038004     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0459     Document Type: Article

References (47)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481-8.
2. Rebillard A, Lefeuvre-Orfila L, Gueritat J, Cillard J. Prostate cancer and physical activity: adaptive response to oxidative stress. Free Radic Bio Med 2013;60:115-24.
3. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000;9:795-804.
4. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000;92:61-8.
5. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1403-9.
6. Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, et al. Prostate, lung, colorectal and ovarian cancer screening trial. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 2007;99:1200-9.
7. Richman EL, Carroll PR, Chan JM. Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer 2012;131:201-10.
8. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169:517-23.
9. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
10. Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 2008;112:1254-63.
11. Chen R, Ren S, Meng T, Aguilar J, Sun Y. Impact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysis. PLoS One 2013;8:e74775.
12. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, et al. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol 2013;8:170.
13. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 1992;89:2399-403.
14. Fimognari C, Hreli P. Sulforaphane as a promising molecule for fighting cancer. Muta Res 2007;635:90-104.
15. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 1997;94:10367-72.
16. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 2007;64:1105-27.
17. Talalay P, Fahey JW, Holtzclaw WD, Prestera T, Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett 1995;82-83: 173-9.
18. Ho E, Beaver LM, Williams DE, Dashwood RH. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr 2011;2:497-510.
19. Wong CP, Hsu A, Buchanan A, Palomera-Sanchez Z, Beaver LM, Houseman EA, et al. Effects of sulforaphane and 3,3′-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One 2014;9:e86787.
20. Phé V, Cussenot O, Rouprêt M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010;105:1364-70.
21. Zhang C, Su ZY, Khor TO, Shu L, Kong AN. Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochem Pharmacol 2013;85:1398-404
22. Keum YS, Khor TO, Lin W, Shen G, Kwon KH, Barve A, et al. Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm Res 2009;26: 2324-31.
23. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 2004;64:5767-74.
24. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med 2007;232:227-34.
25. Clarke JD, Hsu A, Yu Z, Dashwood RH, Ho E. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol Nutri & Food Res 2011;55:999-1009.
26. Hauptstock V, Kuriakose S, Schmidt D, Düster R, Müller SC, von Ruecker A, et al. Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide. Biochem Biophys Res Commun 2011;412:606-11.
27. Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci USA 2009;106:16663-8.
28. Kim SH, Singh SV. DL-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Mol Cancer Ther 2009; 8:1946-54.
29. Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res 2009;69:2117-25.
30. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T , et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171:1141-7.
31. Kensler TW, Egner PA, Fahey JW, Jacobson LP, Stephenson KK, Ye L , et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev 2005;14:2605-13.
32. Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL , et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 2006;55:53-62.
33. Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, et al. Sulforaphane treatment of autism spectrum disorder (ASD). PNAS 2014; 111:1555-5.
34. Houghton CA, Fasset RG, Coombes JS. Sulforaphane: translational research from laboratory bench to clinic. Nutr Rev 2013;71:709-26.
35. MSKCC. Available from: www.mskcc.org/nomograms/prostate/psa/psa-doubling-time.
36. Nakonezny PA, Shull RD. MASM26: Hettmansperger and McKean linear model aligned rank test for the single covariate and one-way ANCOVA case (SAS). J Mod Appl Stat Methods 2007;6:336-340.
37. Traka M, Gasper AV, Melchini A, Bacon JR, Needs PW, Frost V, et al. Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS ONE 2008;3:e2568.
38. Bauer CM, Johnson EK, Beebe-Dimmer JL, Cooney KA. Prevalence and correlates of vitamin and supplement usage amongst men with prostate cancer. Integr Cancer Ther 2012;11:83-89.
39. Suzuki Y, Miyoshi N, Isemura M. Health-promoting effects of green tea. Proc Jpn Acad Ser B Phys Biol Sci 2012;88:88-101.
40. Kroeger N, Belldegrun AS, Pantuck AJ. Pomegranate extracts in the management of men's urologic health: scientific rationale and preclinical and clinical data. Evid Based Complement Alternat Med 2013;2013:701434.
41. Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 2008;7:16.
42. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemo-prevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40.
43. Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, Thrasher JB, Kambhampati S, et al. Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial. PLoS One 2013;8:e68331.
44. Lazarevic B, Hammarström C,Yang J,Ramberg H,Diep LM, Karlsen SJ,et al. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br J Nutr 2012;108:2138-47.
45. deVere White RW, Tsodikov A, Stapp EC, Soares N, Fujii SEH, Hackman RM. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer 2010;62:1036-43.
46. Schröder FH, Roobol MJ, Boevé ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol 2005;48:922-30.
47. Thomas R, Williams M, Sharma H, Chaudry A, Bellamy P. A double-blind, placebo-controlled randomized trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer- the UK NCRN Pomi-T study. Prostate Cancer Prostatic Dis 2014;17:180-6.